Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
Japanese pharma tries to downplay appearance of hostile bid driven largely by interest in Ranexa.
Japanese pharma tries to downplay appearance of hostile bid driven largely by interest in Ranexa.